BridgeBio’s stock was up after it announced the Phase III trial met its endpoints. Image credit: saepul_bahri / Shutterstock.com. BridgeBio Pharma will seek US approval of its limb-girdle muscular ...
Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...
While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...
Electra is assessing ELA026 for haematologic cancers, following promising initial clinical data. Credit: Motortion Films / Shutterstock.com. Electra Therapeutics has raised $183m in an oversubscribed ...
Neuphoria Therapeutics’ lead candidate, BNC210, has failed to show efficacy in the Phase III AFFIRM-1 trial in social anxiety disorder. Image credit: Blueastro via Shutterstock.com. Neuphoria ...
At CTS Nordics, Arnaud Dourlens explained how Sanofi has engaged between clinical operations and supply teams earlier to ...
Dash Solutions has introduced dashClinical, a payment solution that provides real-time, secure payments to clinical trial ...
Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...
The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback